WCG (WIRB-Copernicus Group) Clinical Services Division Opens Office in Japan

Food and Healthcare Press Releases Wednesday May 23, 2018 08:00
PRINCETON, New Jersey--23 May--PRNewswire/InfoQuest
WCG expands global clinical research support presence

WCG(TM) (WIRB-Copernicus Group(R)) Clinical Services Division, the world's leading provider of solutions that measurably improve the quality and efficiency of clinical research, today announced the opening of the company's new office in Tokyo, Japan. WCG's expanded presence in the Asia-Pacific region will strengthen its ability to support increasingly complex, global clinical trials, particularly in the critical areas of drug and diagnostic development for oncology and central nervous system (CNS) diseases.

"WCG's Tokyo office will be home to our Clinical Services Division in Asia, as well as a center of excellence for our growing Patient Engagement Group," said Donald A. Deieso, PhD, chairman and CEO of WCG. "By expanding WCG's footprint abroad, we are helping to ensure that every trial— especially the most complicated and challenging ones—can benefit from our latest advances in trial optimization, signal detection and patient recruitment."

WCG maintains an active presence in 65 countries around the world, helping research sponsors, contract research organizations (CROs) and investigative sites to work together more effectively to conduct faster, safer, and more predictable clinical trials.

In the past decade, Asia has become an increasingly attractive destination for clinical research, with a clinical trials infrastructure designed to foster speed, cost effectiveness and quality.   With a population of more than four billion people, Asia also provides research sponsors with access to a large number of patients for clinical trial recruitment.

About WCG (WIRB-Copernicus Group)

WCG (WIRB-Copernicus Group) is the world's leading provider of solutions that measurably improve the quality and efficiency of clinical research. The industry's first clinical services organization (CSO), WCG enables biopharmaceutical companies, CROs, and institutions to accelerate the delivery of new treatments and therapies to patients, while maintaining the highest standards of human subject protections. For more information, please visit www.wcgclinical.com or follow us on Twitter @WCGClinical.

Logo- https://mma.prnewswire.com/media/659075/WCG_Logo_Logo.jpg

Latest Press Release

Merck Awarded Australian CRISPR Nickase Patent for Foundational Genome-Editing Technology

- Patent covers paired Cas9 nickase technology to reduce off-target effects, advance gene therapy and research - Expands company's foundational CRISPR cutting and integration IP necessary to correct genetic defects in gene therapy patients - Merck to...

Kaneka officially starts continuous manufacturing under GMP

Kaneka Corporation (Headquarters: Minato-ku, Tokyo; President: Mamoru Kadokura) have installed continuous manufacturing equipment to be applied to pharmaceutical products at Kaneka Singapore Co. (Pte.) Ltd, (Headquarters: Singapore; President: Kazuhiko...

TIENS Group opens new high-tech Experience Store in Shenzhen

TIENS Group, one of leading corporations in the Healthcare industry, unveiled a new high-tech Customer Experience Store in Shenzhen. Li Jinyuan, founder and chairman of TIENS group, announced the official opening of its first store in the world on August...

Sotera Health#s Nordion completes the sale of its medical isotopes business to BWXT

- Nordion's increased focus on gamma technologies supports Sotera Health's company-wide commitment to Safeguarding Global Health(TM) Sotera Health LLC, the world's leading, fully integrated protector of global health, today announced the closing of the...

Menarini Ricerche to Sponsor Cancer Trial in Acute Myeloid Leukemia in USA

Menarini Ricerche, a company of the Menarini Group, announced today that the sponsorship of the ongoing Phase I/II study that is investigating MEN1703/SEL24 for the treatment of patients with relapsed/refractory (R/R) AML in the USA has been transferred...

Related Topics